SEATTLE, Aug. 06, 2018 — Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to dilanubicel (NLA101) for patients with high-risk hematologic malignancies receiving an allogeneic cord blood transplant. Dilanubicel has already received PRIME designation from the European Medicines Agency, and Orphan Drug Designation from the FDA and European Commission. [Read more…]
Cymerus™ MSC treatment leads to improved recovery of cardiac function in preclinical heart attack study
Melbourne, Australia; 31 July 2018: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), is pleased to announce positive efficacy data from a study of its Cymerus mesenchymal stem cells (MSCs) in a preclinical heart attack model. [Read more…]
RichSource Stem Cells, Inc. Announces Non-Invasive Breakthrough Product RICHGEN
August 1, 2018 – Charleston, SC, USA – RichSource Stem Cells, Inc. (RichSource), a leader in the business development and distribution of human tissue allograft combination products and membranes, announced today its own brand product line: RICHGEN. With the introduction of this breakthrough line, the industry is no longer limited to single material post-birth, multipotent cellular products. Available throughout the U.S., the RICHGEN product line is backed by an experienced nationwide team of RichSource Area Vice Presidents who can educate, train and provide support to physician practices and networks. Additionally, RichSource’s simplified and more effective treatment protocols helps to optimize practices and patient results. [Read more…]
Fresenius Medical Care achieves preclinical milestone in its regenerative medicine program for chronic kidney disease
July 30, 2018 – Fresenius Medical Care, the world’s largest provider of dialysis products and services, announced today that its subsidiary Unicyte AG has achieved a key preclinical milestone in its regenerative medicine program for chronic kidney disease. The company was able to confirm a disease modifying potential for its proprietary nano-Extracellular Vesicles (“nEVs” are stem cell-derived particles that support communication between cells) in a second preclinical model of chronic kidney disease. [Read more…]
Irvine Scientific Introduces Chemically-Defined Natural Killer Cell Expansion Medium for Immunotherapy & Translational Research Applications
The first chemically-defined, animal component-free cell culture medium for natural killer (NK) cells
July 2018, Santa Ana, Calif. — Irvine Scientific, an industry leader in the development and manufacture of cell culture media, announced the introduction of PRIME-XV® NK Cell CDM— the first commercially available chemically-defined (CDM), animal component-free (ACF) medium for the ex vivo expansion of NK cells. The advanced medium delivers natural killer (NK) cell expansion while preserving NK cell potency and functionality. [Read more…]
- « Previous Page
- 1
- …
- 230
- 231
- 232
- 233
- 234
- …
- 338
- Next Page »